Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Fellowship - Priority Announcement: Infection and Immunity

Direct Payment

$120,000.00

The development of gene therapy as a cure for primary immune deficiencies

EF 2019-20

Résumé
Primary immune deficiencies (PIDs) are a group of life-threatening diseases that originate from abnormalities in genes that regulate cells of the immune system. If left untreated, most PIDs lead to premature death due to fulminant infections, autoimmunity, or cancer. In the most severe forms, bone marrow transplant (BMT) is needed for survival. Although BMT can be lifesaving, matched donors are not available for all patients. Moreover, BMT comes with the risk a devastating complication called graft-versus-host-disease (GvHD), which can lead to severe disease and even death. Gene therapy (GT) is a novel treatment which consists in collecting the blood stem cells of the affected patients and directly correcting the mutated gene by using a viral vector. The repaired cells are then reinfused into the patients, thus permanently restoring a functional immune system. This ingenious method eliminates both the need to find a donor and the risk of GvHD. My project proposes to study GT for Wiskott-Aldrich syndrome (WAS) and DOCK8 deficiency, two closely related PIDs that share many common clinical features including a susceptibility to deadly infections, severe allergies, recurrent autoimmunity, and early-onset cancers. Without treatment, survival is low. We first want study the efficacy of GT at curing autoimmunity in WAS, evaluating the kinetics of recovery of regulatory cells in patients currently enrolled in our GT clinical trial. We also plan develop GT for patients with DOCK8 deficiency by first showing safety and efficacy of GT in an animal model with Dock8 deficiency and show that the immune defects can be corrected, before moving on to clinical trials. This research will lead to improved treatment modalities for these two devastating diseases, and hopefully pave the way for future applications of GT in other similar diseases.
Programme
Fellowship - Priority Announcement: Infection and Immunity
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
417663
Name
Labrosse Roxane
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
The development of gene therapy as a cure for primary immune deficiencies
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Infection and Immunity
Keyworddelim
Autologous Transplant; Cellular Therapy; Dock8 Deficiency; Gene Therapy; Hematopoietic Stem Cell Transplant; Immunodeficiency; Primary Immune Deficiency; Viral Vectors; Virology; Wiskott-Aldrich Syndrome
Abstract
Primary immune deficiencies (PIDs) are a group of life-threatening diseases that originate from abnormalities in genes that regulate cells of the immune system. If left untreated, most PIDs lead to premature death due to fulminant infections, autoimmunity, or cancer. In the most severe forms, bone marrow transplant (BMT) is needed for survival. Although BMT can be lifesaving, matched donors are not available for all patients. Moreover, BMT comes with the risk a devastating complication called graft-versus-host-disease (GvHD), which can lead to severe disease and even death. Gene therapy (GT) is a novel treatment which consists in collecting the blood stem cells of the affected patients and directly correcting the mutated gene by using a viral vector. The repaired cells are then reinfused into the patients, thus permanently restoring a functional immune system. This ingenious method eliminates both the need to find a donor and the risk of GvHD. My project proposes to study GT for Wiskott-Aldrich syndrome (WAS) and DOCK8 deficiency, two closely related PIDs that share many common clinical features including a susceptibility to deadly infections, severe allergies, recurrent autoimmunity, and early-onset cancers. Without treatment, survival is low. We first want study the efficacy of GT at curing autoimmunity in WAS, evaluating the kinetics of recovery of regulatory cells in patients currently enrolled in our GT clinical trial. We also plan develop GT for patients with DOCK8 deficiency by first showing safety and efficacy of GT in an animal model with Dock8 deficiency and show that the immune defects can be corrected, before moving on to clinical trials. This research will lead to improved treatment modalities for these two devastating diseases, and hopefully pave the way for future applications of GT in other similar diseases.
Competitiondate
201910
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Labrosse, Roxane
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~